Search

Your search keyword '"Endris, Volker"' showing total 495 results

Search Constraints

Start Over You searched for: Author "Endris, Volker" Remove constraint Author: "Endris, Volker"
495 results on '"Endris, Volker"'

Search Results

1. BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study

3. A “Two-in-One Hit” Model of Shortcut Carcinogenesis in MLH1 Lynch Syndrome Carriers

4. Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing

5. Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing

7. Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study

8. Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors

9. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts

13. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study

14. The BRCA2 mutation status shapes the immune phenotype of prostate cancer

19. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia

21. Supplementary Patient Data from NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

22. Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

23. Supplementary Table S1 from NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

24. Supplementary Tables S1-S7 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

25. Data from NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

26. Supplementary Figure S2 from NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

27. Supplementary Figures S1-S10 from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

28. Supplementary Methods from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

29. A “two-in-one hit” model of shortcut carcinogenesis in MLH1 Lynch syndrome carriers

30. Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene

31. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

32. BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study

33. EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial

35. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial

37. Precision oncology based on omics data: The NCT Heidelberg experience

40. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer

41. Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary

42. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine

43. Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis

44. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers

45. Distinct Mutational Profile of Lynch Syndrome Colorectal Cancers Diagnosed under Regular Colonoscopy Surveillance

47. Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies

48. Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine.

49. Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field

50. KRAS/GNAS‐testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound‐guided workup of suspected mucinous neoplasms of the pancreas

Catalog

Books, media, physical & digital resources